This reverse merger fundamentally alters Skye's business, shifting focus to Redx's pipeline. Current SKYE shareholders face significant dilution and a change of control. Monitor the proxy statement for detailed exchange ratio calculations and the timeline for shareholder votes. The stock's reaction will depend on investor perception of Redx's pipeline value versus the dilution and CVR structure.
Price Chart
Executive Summary
Skye Bioscience (SKYE) entered into a definitive transaction agreement to acquire Redx Pharma Limited via a scheme of arrangement. The deal values Redx at $161 million and includes a concurrent PIPE of $125 million (with a $68 million tranche from the Securities Purchase Agreement). Skye will issue shares to Redx shareholders based on an exchange ratio, and existing Skye stockholders will receive contingent value rights (CVRs). The transaction constitutes a change of control of Skye, with Redx designating the post-closing board and management. A 1-for-8 reverse stock split was filed to regain Nasdaq compliance. The filing is a transformative reverse merger that fundamentally changes Skye's business and capital structure, making it a significant event for current SKYE shareholders who will see their ownership diluted and the company's direction shift to Redx's pipeline.
Key Financial Metrics
Key Facts
- Skye Bioscience (SKYE) agreed to acquire Redx Pharma Limited in a reverse merger valued at $161 million for Redx.
- A concurrent PIPE of $125 million is planned, with a $68 million tranche documented in a Securities Purchase Agreement.
- The transaction constitutes a change of control of Skye, with Redx designating the post-closing board and management.
- Existing Skye stockholders will receive one contingent value right (Acquiror Legacy CVR) per share held pre-closing.
- A 1-for-8 reverse stock split was filed on August 12, 2026, effective August 24, 2026, to regain Nasdaq compliance.
- The deal is subject to shareholder approvals from both Skye and Redx, court sanction, and other customary conditions, with an end date of August 14, 2027.
Financial Impact
Redx valued at $161M; PIPE of $125M ($68M tranche documented); Skye's pre-money equity value set at $14.5M with a $2M target net cash adjustment.
Risk Factors
- Shareholder approval may not be obtained from either Skye or Redx stockholders.
- The transaction may not close by the August 14, 2027 end date.
- Integration risks and potential value destruction from the reverse merger structure.
- The CVRs for existing Skye stockholders may have no value.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-056966 |
| Exhibit: ex031-skyebioscienceincx.htm | 0001628280-26-056966 |
| Document: skye-20260814xex106xpipese.htm | 0001628280-26-056966 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 20, 2026 6w ago | DEFA14A | $0.2809 $1.77 | ▲ +528.34% | ▲ +528.34% | $1.68 (+498.08%) |
Aug 14, 2026 7w ago | 8-K | $0.5015 $1.99 | ▲ +296.81% | ▲ +298.80% | $1.68 (+235.00%) |
Aug 14, 2026 7w ago | Press Release | $0.5015 $1.99 | ▼ −296.81% | ▼ −298.80% | $1.68 (−235.00%) |
May 15, 2026 20w ago | 8-K | $0.7780 $0.7184 | ▲ +7.66% | ▲ +9.24% | $1.68 (−115.94%) |
May 12, 2026 20w ago | Press Release | $0.8140 $0.7800 | ▲ +4.18% | ▲ +2.45% | $1.68 (−106.39%) |
Apr 29, 2026 22w ago | 3 | $0.8940 $0.8500 | ▼ −4.92% | ▼ −10.97% | $1.68 (+87.92%) |
Apr 16, 2026 24w ago | DEFA14A | $0.7500 $0.8200 | ▲ +9.33% | ▲ +3.52% | $1.68 (+124.00%) |
Apr 2, 2026 26w ago | Press Release | $0.6980 $0.8790 | ▲ +25.93% | ▲ +16.05% | $1.68 (+140.69%) |
Mar 10, 2026 29w ago | Press Release | $0.7210 $0.7260 | ▲ +0.69% | ▲ +0.17% | $1.68 (+133.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access